USP17L5 Inhibitors
USP17L5 inhibitors comprise a varied group of chemical compounds that decrease the functional activity of USP17L5, a deubiquitinating enzyme involved in various cellular processes including DNA damage response, cell cycle regulation, and apoptosis. Veliparib inhibits PARP enzymes, leading to an accumulation of unrepaired DNA damage and reduced activity of USP17L5 in DNA repair mechanisms. SB 431542 and LY 294002 target upstream elements of TGF-β and PI3K/Akt pathways, respectively, pathways where USP17L5 plays a role; their inhibition results in diminished signaling cascades that would normally engage USP17L5. Similarly, PD 98059 and U0126 obstruct the MEK/ERK pathway, while SP600125 targets JNK signaling, all of which are pathways modulated by USP17L5; the inhibition of these pathways reduces the enzyme's opportunity to modulate cellular responses to stress and growth signals. Bortezomib and MG-132 are proteasome inhibitors that lead to the buildup of ubiquitinated protein substrates, therefore indirectly impeding the deubiquitinating function of USP17L5 by preventing substrate turnover.
Further contributing to the inhibition of USP17L5's activity, Wortmannin serves as another PI3K pathway inhibitor, supporting the redundancy of targeting this particular pathway to ensure a comprehensive reduction in USP17L5-related activities. PF-00562271 and ZM-447439 disrupt cell cycle-related processes by inhibiting focal adhesion kinase and Aurora kinase, respectively, affecting phases of the cell cycle where USP17L5 is implicated. C646, by hindering histone acetyltransferase activity, indirectly influences gene expression patterns that could impact the functional activity of USP17L5, particularly in pathways where regulation of gene expression is essential. Collectively, these inhibitors utilize diverse biochemical mechanisms to diminish the cellular processes and signaling pathways that USP17L5 is known to modulate, ensuring a broad-spectrum approach to reducing its functional activity.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Veliparib | 912444-00-9 | sc-394457A sc-394457 sc-394457B | 5 mg 10 mg 50 mg | $178.00 $270.00 $712.00 | 3 | |
A PARP inhibitor that can interfere with the repair of DNA single-strand breaks. As USP17L5 is implicated in DNA damage response, inhibition of PARP can lead to an accumulation of DNA damage, indirectly reducing the functional activity of USP17L5 in DNA repair processes. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
An inhibitor of the TGF-β receptor that impedes TGF-β signaling. Given that USP17L5 has been shown to regulate pathways involving TGF-β, SB-431542 can indirectly diminish USP17L5 functional activity by inhibiting upstream signals that would otherwise engage USP17L5. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A PI3K inhibitor that blocks the PI3K/Akt pathway, which is crucial for cell survival and growth. By inhibiting PI3K, LY 294002 can indirectly diminish the activity of USP17L5, which is known to modulate cell proliferation and survival pathways. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
An MEK inhibitor that disrupts the MEK/ERK pathway, a pathway that USP17L5 has been implicated in. Inhibition of MEK would lead to a reduction in ERK signaling, thereby indirectly diminishing the functional activity of USP17L5 related to this signaling pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
A JNK inhibitor that can block JNK signaling involved in stress responses and apoptosis. As USP17L5 is linked to apoptotic pathways, the inhibition of JNK signaling by SP600125 can indirectly lead to a decrease in USP17L5 activity associated with stress responses. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
A proteasome inhibitor that leads to the accumulation of ubiquitinated proteins by inhibiting their degradation. Since USP17L5 is a deubiquitinating enzyme, MG132 can indirectly diminish its functional activity by preventing the turnover of its ubiquitinated substrates. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
An inhibitor of MEK1/2 that can prevent the activation of the ERK pathway. As ERK signaling can be modulated by USP17L5, the use of U0126 can indirectly reduce the functional activity of USP17L5 by impeding the signaling pathway it influences. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
A potent PI3K inhibitor that can decrease PI3K/Akt signaling. USP17L5 is thought to play a role in PI3K/Akt mediated pathways, and thus the inhibition of PI3K by Wortmannin can indirectly diminish the activity of USP17L5 in these pathways. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
A proteasome inhibitor used to prevent the degradation of ubiquitin-protein conjugates. Given that USP17L5 functions as a deubiquitinase, Bortezomib can indirectly reduce USP17L5's functional activity by disrupting the degradation pathway it is part of. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $150.00 $349.00 | 15 | |
An Aurora kinase inhibitor that affects cell division by disrupting chromosome alignment and segregation. As USP17L5 is implicated in cell cycle regulation, ZM-447439 can indirectly diminish the functional activity of USP17L5 in the context of mitosis. | ||||||